Search research articles
Contact Us
Filters
Showing results (11-20 of 24) with videos related to
Page
of 3
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 13, 2017
Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance)
Charles L Shapiro, James P Moriarty, Stacie Dusetzina, et al.
JAMA Network Open
|
December 1, 2020
Assessment of Cancer Therapy Evaluation Program Advocacy and Inclusion Rates of People Living With HIV in Anti-PD1/PDL1 Clinical Trials
Joshua E Reuss, Diana Stern, Jared C Foster, et al.
Cancer
|
July 13, 2017
Comparative "nocebo effects" in older patients enrolled in cancer therapeutic trials: Observations from a 446-patient cohort
Jared C Foster, Jennifer G Le-Rademacher, Josephine L Feliciano, et al.
Journal of Geriatric Oncology
|
April 21, 2018
Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611)
Michael Tallarico, Jared C Foster, Drew Seisler, et al.
JAMA
|
December 29, 2016
Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial
Andrew L Himelstein, Jared C Foster, James L Khatcheressian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 20, 2016
Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527
Rachel A Freedman, Jared C Foster, Drew K Seisler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 30, 2021
Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas
Geraldine O'Sullivan Coyne, Shivaani Kummar, James Hu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 18, 2021
Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0
Sara M Tolaney, Elizabeth Garrett-Mayer, Julia White, et al.
JCO Precision Oncology
|
April 30, 2021
Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Multicenter Phase II Trial
Alice P Chen, Shivaani Kummar, Nancy Moore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 11, 2023
Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP
Jennifer K Litton, Meredith M Regan, Lajos Pusztai, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 24) with videos related to
Sort By:
Page
of 3
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 13, 2017
Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance)
Charles L Shapiro, James P Moriarty, Stacie Dusetzina, et al.
JAMA Network Open
|
December 1, 2020
Assessment of Cancer Therapy Evaluation Program Advocacy and Inclusion Rates of People Living With HIV in Anti-PD1/PDL1 Clinical Trials
Joshua E Reuss, Diana Stern, Jared C Foster, et al.
Cancer
|
July 13, 2017
Comparative "nocebo effects" in older patients enrolled in cancer therapeutic trials: Observations from a 446-patient cohort
Jared C Foster, Jennifer G Le-Rademacher, Josephine L Feliciano, et al.
Journal of Geriatric Oncology
|
April 21, 2018
Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611)
Michael Tallarico, Jared C Foster, Drew Seisler, et al.
JAMA
|
December 29, 2016
Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial
Andrew L Himelstein, Jared C Foster, James L Khatcheressian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 20, 2016
Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527
Rachel A Freedman, Jared C Foster, Drew K Seisler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 30, 2021
Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas
Geraldine O'Sullivan Coyne, Shivaani Kummar, James Hu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 18, 2021
Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0
Sara M Tolaney, Elizabeth Garrett-Mayer, Julia White, et al.
JCO Precision Oncology
|
April 30, 2021
Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Multicenter Phase II Trial
Alice P Chen, Shivaani Kummar, Nancy Moore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 11, 2023
Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP
Jennifer K Litton, Meredith M Regan, Lajos Pusztai, et al.
Page
of 3